Efficacy of Escitalopram in the Treatment of Internet Addiction

This study has been completed.
Sponsor:
Collaborator:
Forest Laboratories
Information provided by:
Mount Sinai School of Medicine
ClinicalTrials.gov Identifier:
NCT00565422
First received: November 28, 2007
Last updated: May 23, 2008
Last verified: May 2008

November 28, 2007
May 23, 2008
December 2002
Not Provided
length of non-essential Internet use in hours/week as well as CGI-Improvement [ Time Frame: baseline and biweekly for 10 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00565422 on ClinicalTrials.gov Archive Site
ratings on depression, anxiety, impulsivity, self-esteem, obsessive-compulsive symptoms [ Time Frame: baseline and biweekly for 10 weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Efficacy of Escitalopram in the Treatment of Internet Addiction
Efficacy of Escitalopram in the Treatment of Internet Addiction

The purpose of this study was to determine whether Lexapro (Escitalopram) is safe and effective in treating problematic internet use.

Many individuals experience marked distress and functional impairments as a result of their perceived inability to control their 'non-essential' (non-job/school related) use of the Internet. Frequently these people develop a preoccupation with the Internet, a need for escape to the Internet, and increasing irritability when trying to cut back use of the Internet. There have been no studies to date looking at the effectiveness of medications in the treatment of this disorder. In our clinical experience, we find these patients with Internet addiction usually respond to serotonin reuptake inhibitors within 12 weeks. This study will examine the efficacy of escitalopram in Internet addiction among adults.

Interventional
Phase 4
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Internet Addiction
Drug: Escitalopram
10 mg/day
Other Name: Lexapro
Experimental: Single Arm
Escitalopram
Intervention: Drug: Escitalopram
Dell'Osso B, Hadley S, Allen A, Baker B, Chaplin WF, Hollander E. Escitalopram in the treatment of impulsive-compulsive internet usage disorder: an open-label trial followed by a double-blind discontinuation phase. J Clin Psychiatry. 2008 Mar;69(3):452-6.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
31
October 2004
Not Provided

Inclusion Criteria:

  1. Subject has signed an informed consent form
  2. Current diagnosis of Internet addiction
  3. Age ³ 18
  4. Subject must be able to take oral medication
  5. Subject may be in psychotherapy initiated at least three months prior to Screening. Subject must not discontinue or otherwise alter this therapy during the study.
  6. In the opinion of the investigator, the subject is capable of complying with all study procedures.

Exclusion Criteria:

  1. Current suicidal or homicidal ideation
  2. Subject has a primary diagnosis of schizophrenia or other psychotic disorders
  3. Subject has a primary diagnosis of Bipolar I disorder
  4. Current pedophilia
  5. Current DSM-IV diagnosis of substance dependence or abuse, excluding nicotine
  6. Women of child-bearing potential who are pregnant, nursing, or not using contraception
  7. Use of antidepressants at a therapeutic level for the treatment of problematic internet use within 2 weeks prior to study entry (or 4 weeks for use of MAOIs, or 6 weeks for use of fluoxetine)
  8. Current use of antidepressants at a therapeutic level for the treatment of a disorder other than problematic internet use
  9. Subject has any organic mental disorder
  10. Clinically significant unstable medical disorder
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00565422
LXP-MD-09, 01-1174
No
Dr. Eric Hollander, Mount Sinai School of Medicine
Mount Sinai School of Medicine
Forest Laboratories
Principal Investigator: Eric Hollander, MD Mount Sinai School of Medicine
Mount Sinai School of Medicine
May 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP